Comparison of select COVID-19 vaccines 2022, by efficacy

Published by
Matej Mikulic,
Mar 7, 2023
As of February 2022, mRNA-based vaccine Comirnaty, developed by Pfizer/Biontech, was the leading COVID-19 vaccine by efficacy rate, showing around 95 percent of efficacy against COVID-19. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by efficacy.

Comparison of select COVID-19 vaccines worldwide as of 2022, by efficacy

Loading statistic...

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2022

Region

Worldwide

Survey time period

as of February 2022

Supplementary notes

Efficacy figures based on phase 3 studies when different variants were prominent.

Citation formats
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$69 USD $49 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Moderna Inc. "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Statistics on Moderna Inc.

Market overview

6

Key figures

5

Competitors

4

Focus: COVID-19

8

Further related statistics

21

Further Content: You might find this interesting as well

Topics

ModernaGlobal pharmaceutical industryPfizerBioNTechVaccinations in the U.S.
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Learn more about how Statista can support your business.
Menu